Escolar Documentos
Profissional Documentos
Cultura Documentos
Businesses
5 key growth verticals with the aim to deliver sustainable
long term value for patients, partners, healthcare
systems across the globe.
3 businesses
1. Custom research (Syngene)
2. Clinical development (Clinigene)
3. Biopharmaceuticals (Biocon)
Bangalore Subsidiary
Bangalore Subsidiary
Bangalore Subsidiary
Malaysia Subsidiary
Switzerland
Subsidiary
Abu Dhabi
Joint venture
company
Subsidiary Companies
1. Syngene International Limitedis a custom research
organization offering synthetic chemistry and molecular
biology services for early stage drug discovery and
development.
2. Biocon Pharma Limited (BPL)began as a joint venture
with CIMAB to develop and market a range of monoclonal
antibodies and cancer vaccines.
3. Biocon Research Limited(BRL)is a wholly owned
subsidiary set up to undertake discovery and development
research work in biologics, antibody molecules and proteins.
Subsidiary Companies
4. NeoBiocon FZ LLCis a research and marketing
pharmaceutical company based in Abu Dhabi.
5. Biocon SAis a wholly owned subsidiary in Switzerland
primarily engaged in the development and commercialization
of biopharmaceuticals across the globe. Clinical Development
of Insulin is currently ongoing in the European region.
6. Biocon SDN. BHD. is a wholly owned subsidiary in Malaysia
to set up a state of the art manufacturing facility at BioXcell a
biotechnology park promoted by the Government of Malaysia.
Vision
To enhance global healthcare through innovative and affordable
biopharmaceuticals for patients, partners and healthcare
systems across the globe
Mission
To be an integrated biotechnology enterprise of global
distinction.
Essential to this mission is excellence in:
- Intellectual asset creation through discovery, research and
development
- State-of-the-art manufacturing capabilities
- Internationally benchmarked quality and regulatory systems
- New medical insight through disease specificclinical research
- Customer relationship through outstanding products and
services
- Human resource development through training , mentoring
and empowering
- Management of research and business partnerships
Values
Integrity and Ethical Behaviour
Performance driven work culture
Value Creation through Innovation & Differentiation
Quality through Compliance & Best Practices
Collaboration, Team Work & Mutual Respect
Strategic Alliance
BIOCON BRISTOL-MYERS SQUIBB: 2012
Biocon entered into an option agreement with Bristol-Myers
Squibb for Biocon's IN-105, an oral insulin drug candidate
Biocon to continue development of IN-105
Bristol-Myers Squibb will have an exclusive option to further
develop and commercialize IN-105
History
November
29,1978
1979
Biocons Founding
Day
2000
2001
2006
Biocon inaugurates Biocon
Biopharmaceuticals, India's largest
multi-product Biologics facility at
Biocon Park
1989
Unilever plc. acquires Biocon
Biochemicals Ltd. in Ireland and
merges it with its subsidiary,
Quest International
Biocon is the first Indian biotech
company to receive US funding for
proprietary technologies
1993
Biocon's R&D and manufacturing
facilities receive ISO 9001
certification from RWTUV,
Germany
2004
2003
Biocon is the first company
worldwide to develop human
insulin on a Pichia expression
system